| Evidence domain | Finding | Evidence type | Key source/date/DOI/PMID | Confidence / limitation |
|---|---|---|---|---|
| Foundational genetics | In consanguineous Pakistani family PKDF468, homozygosity mapping defined DFNB88 at 2p11.2 (maximum two-point LOD 4.74), and exome sequencing identified homozygous **ELMOD3 c.794T>C (p.Leu265Ser)** segregating with hearing loss. The variant was absent from 524 ethnically matched control chromosomes, 1000 Genomes, and 6,500 NHLBI-ESP individuals. (pqac-00000002, pqac-00000003) | Human pedigree, linkage, segregation, exome sequencing | Jaworek et al.; published 2013-09-05; DOI [10.1371/journal.pgen.1003774](https://doi.org/10.1371/journal.pgen.1003774); PMID **24039609** (pqac-00000001, pqac-00000020) | **High for this family and variant.** Replication and disease-wide genotype–phenotype data remain sparse; evidence does not establish population-level penetrance or prevalence. |
| Human phenotype | Affected relatives had **bilateral, prelingual, severe-to-profound mixed hearing loss**, including a substantial conductive component in at least one documented audiogram. No clear vestibular, skin, renal, or retinal abnormalities were identified; temporal-bone CT was largely normal. (pqac-00000001, pqac-00000002) | Human clinical and audiologic characterization | Jaworek et al.; 2013-09-05; DOI [10.1371/journal.pgen.1003774](https://doi.org/10.1371/journal.pgen.1003774); PMID **24039609** | **Moderate.** Directly observed but based on one extended family; phenotype frequencies, longitudinal progression, and quality-of-life scores were not reported. |
| Biochemical mechanism | ELMOD3 localized to actin-rich cochlear stereocilia and exhibited GAP activity toward **ARL2**; p.Leu265Ser impaired localization to actin-based structures and **abolished recombinant ELMOD3 ARL2-GAP activity**, supporting a loss-of-function mechanism affecting small-GTPase/cytoskeletal regulation. (pqac-00000001, pqac-00000003) | Rodent tissue localization, transfected-cell assays, recombinant-protein biochemistry | Jaworek et al.; 2013-09-05; DOI [10.1371/journal.pgen.1003774](https://doi.org/10.1371/journal.pgen.1003774); PMID **24039609** | **Moderate-to-high mechanistic support.** Functional effect was demonstrated in vitro, but the complete causal sequence in human cochlear cells remains partly inferred. |
| Elmod3-null mouse | CRISPR-generated homozygous null mice developed moderate, progressive hearing loss beginning at 2 months; ABR abnormalities involved all tested frequencies, and DPOAE shifts implicated outer-hair-cell dysfunction. Mutants showed reduced cochlear F-actin, shortened/fused inner-hair-cell stereocilia, progressive outer-hair-cell stereocilia degeneration, reduced ARL2 expression, and normal vestibular behavior. (pqac-00000014, pqac-00000015, pqac-00000016, pqac-00000017) | In vivo genetic model; ABR, DPOAE, histology, immunostaining, SEM | Li et al.; advance publication 2019-10-19; DOI [10.1093/hmg/ddz240](https://doi.org/10.1093/hmg/ddz240) (pqac-00000014) | **High for mouse phenotype; moderate for human translation.** Mouse onset/severity differs from the documented prelingual severe-to-profound human phenotype, and only homozygous mice were affected. |
| 2023 iPSC transcriptomics | Patient-derived iPSCs with heterozygous **ELMOD3 c.512A>G (p.His171Arg)** and an isogenic CRISPR-corrected line showed altered cytoskeletal, ion-transport, ear-morphogenesis, GPCR, PI3K–AKT, cAMP, calcium-signaling, and cell-adhesion programs; 26 downregulated genes related to ion transmembrane transport and 16 to potassium transport were reported. **This variant causes autosomal-dominant progressive hearing loss and is not DFNB88-specific evidence.** (pqac-00000009, pqac-00000019) | Patient-derived iPSC model, CRISPR correction, bulk RNA-seq, computational enrichment, qRT-PCR | Liu et al.; published 2023-09-14; DOI [10.1371/journal.pone.0288640](https://doi.org/10.1371/journal.pone.0288640) | **Supporting ELMOD3 biology only.** Undifferentiated iPSCs are not cochlear hair cells; control comparisons were confounded by sex and other genomic differences, and the genotype/inheritance differs from DFNB88. |
| Population rarity | A 2024 review identified 51 ARNSHL genes in Pakistan. Thirteen common genes accounted for more than half of profound hearing-loss cases; other genes, the category containing rare ELMOD3, each contributed **<2%**. (pqac-00000013) | Population-focused literature review | Shadab et al.; accepted 2024-01-02; DOI [10.1111/jcmm.18119](https://doi.org/10.1111/jcmm.18119) | **Low-to-moderate for ELMOD3 frequency.** The <2% figure is a category-level estimate, not a DFNB88-specific prevalence or carrier-frequency measurement. |
| Diagnostics and management | Practical diagnosis combines newborn/clinical audiology, air- and bone-conduction testing, tympanometry/OAE/ABR as appropriate, and molecular confirmation of **biallelic pathogenic ELMOD3 variants**, preferably through a comprehensive hearing-loss panel with CNV analysis or exome/genome sequencing. Current management is phenotype-directed hearing rehabilitation with hearing aids, cochlear-implant assessment, speech-language support, educational accommodations, and genetic counseling. General reviews state that hearing aids and cochlear implants remain the principal corrective options. (pqac-00000011, pqac-00000012) | Clinical application extrapolated from hereditary-hearing-loss standards; disease molecular evidence | Petit et al.; 2023; DOI [10.1038/s41576-023-00597-7](https://doi.org/10.1038/s41576-023-00597-7); Zhang et al.; 2024; DOI [10.1002/advs.202402166](https://doi.org/10.1002/advs.202402166) | **Moderate.** No DFNB88-specific diagnostic guideline, validated biomarker, treatment algorithm, or outcome series was identified. Conductive components require independent middle-ear evaluation rather than attribution to ELMOD3 alone. |
| Trials and disease-modifying therapy | No DFNB88/ELMOD3-specific interventional trial or approved pharmacologic, RNA, cell, editing, or gene-replacement therapy was identified. Hereditary-deafness gene therapy has restored hearing in more than 20 mouse models and reached clinical translation for **OTOF/DFNB9**, but this should not be extrapolated as demonstrated efficacy for DFNB88. (pqac-00000012) | Clinical-trial search and contemporary therapeutic review | Zhang et al.; 2024; DOI [10.1002/advs.202402166](https://doi.org/10.1002/advs.202402166) | **High confidence that evidence is absent in the searched sources, not proof that no unindexed study exists.** ELMOD3 therapy remains preclinical/conceptual, with delivery, target-cell, timing, efficacy, and safety unresolved. |


*Table: Compact appraisal of the principal human, biochemical, mouse, population, diagnostic, and therapeutic evidence for ELMOD3-associated DFNB88. It separates disease-specific findings from supportive but non-DFNB88 ELMOD3 research.*